Phase II study of 1L pembrolizumab in pts ≥ age 70 with PDL1+ NSCLC by @NadalErnest and @gecp_org now @LungCaJournal. 1Y OS rate 62% with mOS 19.2m. Confirms expectations, helpful to have prospective data. Age should not deter proper therapy. https://t.co/SqLywYzNK1 (@StephenVLiu)

JUST IN: @FDAOncology approved dostarlimab (PD-1 inh, GSK) w/carboplatin+paclitaxel, followed by single-agent dostarlimab, for dMMR/MSI-H metastatic endometrial cancer. Approval based on RUBY trial published in @NEJM 2023 https://t.co/QAkLNAnmWy @OncoAlert @OncBrothers (@DrChoueiri)

WATCH: Dr Mirza on the FDA Approval of Dostarlimab Plus Chemotherapy in dMMR/MSI-H Endometrial Cancer @MirzaCPH @Rigshospitalet @US_FDA #gyncsm https://t.co/znzrC40eHt (@OncLive)

FDA Approves Dostarlimab Plus Chemotherapy in dMMR/MSI-H Advanced Endometrial Cancer https://t.co/cJNILT0V1t via @targetedonc #MedTwitter #OncTwitter #ecsm (@dawood_findakly)

Hot in #JITC - #ICYMI: Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA dMMR/MSI-H or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET—a phase I, single-arm study https://t.co/CFWk7OrrN7 @AnaOaknin @BPothuri (@jitcancer)

ICYMI: The TIGIT inhibitor domvanalimab & the A2R antagonist etrumadenant enhances the clinical activity of the PD-1 inhibitor zimberelimab when administered as triplet therapy in pts w/ PD-L1–high, metastatic NSCLC. @MLJohnsonMD2 @SarahCannonDocs #lcsm https://t.co/z5dxHeQf1S (@OncLive)

Lenvatinib plus pembrolizumab demonstrated improved ORR compared with sunitinib monotherapy in treatment-naïve patients with advanced RCC regardless of risk status or PD-L1 expression. @motzermd @MSKCancerCenter @kidneycan #KCRS23 #kcsm https://t.co/p1LcSl5Czk (@OncLive)

I’m spoiled➡️Rectal Cancer Trial options: ✔️an investigator trial of AB928 Dual Adenosine Receptor Antagonist💊➕AB122 (a PD1⛔️) (PANTHER)➕☢️ ✔️JANUS @JoshSmithMDPhD @ALLIANCE_org 🔌 ✔️ROBIN 💡Add preference for short course☢️in oligo-metastatic to avoid breaks. #CRCSM (@pashtoonkasi)

WATCH: @shilpaonc, of @ClevelandClinic, discusses the enrollment criteria used for the phase 1/2 EV-103 trial in metastatic urothelial carcinoma & highlights next steps for frontline enfortumab vedotin & pembrolizumab in the phase 3 EV-302 trial. #oncology https://t.co/oZoRVYR0cX (@OncLive)

Here, @jasonlukemd shares insight into the final distant metastasis-free survival analysis of #KEYNOTE716 as presented at the @ASCO annual meeting. Learn more here: https://t.co/Nf8A1JbYCH #onctwitter #medtwitter #ASCO2023 #melanoma #pembrolizumab (@OncLearnNetwork)

Extended follow-up results of the #CheckMate274 trial. @MattGalsky @TischCancer & @UroCancerMD @VUMCurology discuss the long-term results showing continued DFS benefits of adjuvant nivolumab vs PBO in high-risk muscle-invasive urothelial cancer patients > https://t.co/367pewfVsM (@urotoday)

According to data from the final OS analysis of the CLEAR study, lenvatinib plus pembrolizumab produced an ORR of 71.3% in treatment-naïve patients with advanced RCC vs 36.7% with sunitinib. @motzermd @MSKCancerCenter @kidneycan #KCRS23 #kcsm https://t.co/NDvc1gD1Ne (@OncLive)

We are continuing to highlight noteworthy research from #ASCO23! Next up, watch @OmidHamidMD, of @angelesclinic, discuss phase 1 findings with fianlimab plus cemiplimab in patients with advanced melanoma. @ASCO #melsm https://t.co/fSpDpEVMQQ (@OncLive)

11/16 #TumorBoardTuesday #RCC Back to our case 🔎 👨🏼‍🦳 Patient starts cabozantinib at 60mg qd 📆 3 mos ✋🏽🦶🏽G3 ⬇️dose reduce to 40mg 🩻scans: PR lasts for one year 🫁single new pulm met 🧐What treatment option do you consider next after progression of pembro/axi and cabo? (@katy_beckermann)

#PostTest Q1️⃣ #TumorBoardTuesday 👉🏽#CME Eval 🔗 https://t.co/06srQ9xkwE 🤔@brian_rini @katy_beckermann taught us treating refractory #RCC test your 🧠 with quick❓ 🧐What tx? 64yo 👴🏽 met RCC (🫁 & adrenal) asympt dz progress (liver) 18mos pembro/axit Wants aggressive tx (@katy_beckermann)

13/16 #TumorBoardTuesday Back to case🔎 64yo👨🏼‍🦳 met #RCC to 🫁 & adrenal 💊pembro/axitinib 📆18 mos PD to liver 🩻PR on cabo: single growing met 💊Cabo & SBRT 🙌🏽 SD for 6 mos 🩻scans: growth in liver & 🫁 🧐What tx do you consider next after progression of pembro/axi and cabo? (@katy_beckermann)

15a/16 #TumorBoardTuesday 🧑🏼‍🔬Ongoing Trials assessing belzutifan in sporadic met #RCC ✨Pembro+lenva: https://t.co/RseK3omjaO ✨Belzu+pembro v placebo+pembro: https://t.co/UIZCuOHgoR ✨Pembro+belzu+lenva OR pembro/Quavo+lenva v pembro+lenva https://t.co/QTUdhDsyb9 (@katy_beckermann)

Pembrolizumab's impact on cystectomy-free survival in BCG unresponsive #BladderCancer from #KEYNOTE057. @GSK_UofT @UofT and @UroDocAsh @MDAndersonNews discuss these promising results and the importance of timely cystectomy to prevent metastatic disease > https://t.co/y646XcpufD (@urotoday)

Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial #ACScancerchat (@drfrankiejs)

My dads late stage melanoma shrank 30% in 6 months on Keytruda but unfortunately had done too much damage already to save his life. Early detection and treatment is the key (@Studio26151)

Professor Scolyer, what is the plan of attack? Are you going to hit it with Ipi+nivo? 10 years ago in June of 2013 I was diagnosed stage 4 melanoma brain and lung mets. Part of checkmate 067, Nivo arm of trial after SRS cyberknife for 3 small brain mets. Best Wishes!!! (@EdWilli63968626)

Pivotal ph2 study in @NatureMedicine showing that combining T-cell gene inflam signat and #TMB in NSCLC stratifies ORR to 1L Pembro plus either lenva/CTLA4/LAG3 combos. 50-60% ORR in “double-high” cohort. 👏@DrRoyHerbstYale @danieltanmd @EnriquetaFelip https://t.co/BaCSZtbaQ9 (@g_mountzios)

🗞️ Published in @TheLancetOncol and co-authored by VHIO’s @crisuarez08, results from the single-arm phase II KEYNOTE-B61 clinical trial support the use of pembrolizumab plus lenvatinib in patients with previously untreated advanced non-clear cell renal cell carcinoma. ➕… https://t.co/qUn891LZBA (@VHIO)

Lenvatinib/Pembrolizumab Benefit Is Upheld in Advanced RCC, Including ICI-Pretreated and Naïve Subgroups @ChungHanLee3 @MSKCancerCenter @kidneycan #KCRS23 #kcsm https://t.co/yU9CWV30fx (@OncLive)

Important talk by @tompowles1 discussing emerging biomarkers for nivolumab + ipilimumab among patients with #mRCC in light of novel findings from the PRISM trial #KCRS23 #Biomarkers #KidneyCancer (@kidneycan)

S6: Immunotherapy Advances and Research 💥Targeting Interleukin-1beta to Overcome Adaptive Immune Resistance in RCC SPARK1 Trial Spartalizumab (PD1) + Canakinumab (IL-1b) #MatthewDallos @Dr_Aggen @kidneycan #KCRS23 (@MikeSerzanMD)

Frontline Lenvatinib Plus Pembrolizumab Produces Superior Responses Vs Sunitinib in Advanced RCC @motzermd @MSKCancerCenter @kidneycan #KCRS23 #kcsm https://t.co/RQML5zNQnC (@OncLive)

The sustained OS benefit observed with pembrolizumab and lenvatinib in the CLEAR study solidifies the doublet’s use as a preferred option for the frontline treatment of patients with advanced RCC. @DrTHut @TexasOncology @SarahCannonDocs #kcsm https://t.co/Jmjj0bMNuC (@OncLive)

An ongoing phase II study led by @DrRoyHerbstYale shows combining pembrolizumab w/other treatments ⬇️ the size of target tumors, resulting in a ⬆️ response rate for patients w/advanced #NSCLC. #lcsm #KEYNOTE495 @SmilowCancer @YaleMed @YNHH @YaleThoracic https://t.co/8nzR0RsY2v (@YaleCancer)

⬆️ FAKi Boosts Anti-PD1 Immunotherapy in Pancreatic Cancer @DrArsenOsipov @danwpaterson @VerastemOncolog @PanCAN @lustgartenfdn @CpcrMsk @DanaFarber_Hale @jgong15 @CedarsSinai @ASCO #defactinib #pembrolizumab #CXCR4 #PDAC 🔻 https://t.co/OQHKJByl0J (@CrozrX)

S7: Oral Abstract 🩸 Circulating KIM-1 is a Minimally Invasive Biomarker Correlated with Response to Nivo in RCC Retrospective analysis of pt treated with Nivo on CM009 ⬇️Decrease in KIM1 a/w PFS HR 0.22! @VincentWenxinXu @DanaFarber_GU @kidneycan #KCRS23 (@MikeSerzanMD)

Study on phase I trial efficacy and safety of #dostarlimab in patients with advanced or recurrent #EndometrialCancer and analysis of tumor #biomarkers as prognostic indicators by Oaknin et al. https://t.co/bIYQrWUY5L @CaraMath @ValentinaBoni7 @BanerjeeSusana @AACR (@CCR_AACR)

Guess who stopped by? @ChungHanLee3, of @MSKCancerCenter! Thanks for speaking with us about the final results of the phase 2 cohort of lenvatinib + pembrolizumab for progressive disease after a PD-1/PD-L1-containing therapy in metastatic clear cell RCC #kcsm @kidneycan (@OncLive)

We spoke with @ChungHanLee3 from @MSKCancerCenter on the use of lenvatinib and pembrolizumab in patients with RCC. #kicsm | @kidneycan (@CancerNetwrk)

⭐️Huge congrats to our friends & colleagues ⁦@jeanyvesblay⁩ ⁦⁦@drcmassard⁩ from France for publishing this study 👉🏼Pembrolizumab in patients with rare & ultra-rare sarcomas (AcSé Pembrolizumab) ⁦@TheLancetOncol⁩ ⁦@OncoAlert⁩ https://t.co/FoSVuMFgKc (@VivekSubbiah)

@EJonasch on the STARLITE 1: a phase 1/2 study of combination 177Lu Girentuximab plus Cabo and Nivo in ccRCC @kidneycan #KCRS23 (@MosheOrnsteinMD)

Dr. @EJonasch presented STARLITE 1 Phase 1/2 trial evaluating 177Lu-Girentuximab plus Cabozantinib and Nivolumab in patients with clear cell RCC. #KCRS23 (@FabioSchutz78)

S3: Trials In Progress ⭐️ STARLITE 1 Phase 1/2 Study of Combo 177Lu Girentuximab + Cabo + Nivo in Treatment Naive ccRCC @EJonasch @MDAndersonNews @DrEHasanov @kidneycan #KCRS23 (@MikeSerzanMD)

#Hematology #Pembrolizumab in relapsed or refractory primary mediastinal large B-cell #lymphoma #PMBCL: final analysis of KEYNOTE-170 | ⁦@BloodJournal⁩ | American Society of Hematology ⁦@ASH_hematology⁩ #lymsm https://t.co/u2dY4mXYfu (@DrRaulCordoba)

5/ 📊 After watching @DrMMurphy's video, what approach would you take to manage asymptomatic or symptomatic, grade 1 or 2 hypothyroidism in a woman w/ #endometrialcancer who is receiving pembrolizumab treatment❓ #ECBrief (@SoMeCME)

Of course, where ICPI and TKI durable responses lie on this axis is anyone’s guess…. I have my first patients about to hit FIVE years from completing their two years of Pembrolizumab for stage IV lung cancer… (@OncoloJo)

Pembrolizumab led to sustained improvements in recurrence-free survival and distant metastasis-free as adjuvant therapy in patients with resected melanoma, according to research led by @jasonlukemd. @OncLive https://t.co/gGyubaTBDO (@UPMCHillmanCC)